



NDA 21882/S-011

**SUPPLEMENT APPROVAL**

Novartis Pharmaceuticals Corporation  
Attention: Joseph Quintavalla, Ph.D.  
Associate Director, Drug Regulatory Affairs  
One Health Plaza  
East Hanover, NJ 07936-1080

Dear Dr. Quintavalla:

Please refer to your Supplemental New Drug Application (sNDA) dated October 22, 2010, received October 22, 2010, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Exjade<sup>®</sup> (deferasirox) Tablets for Oral Suspension.

We acknowledge receipt of your amendments dated November 11, 2010, December 16, 2010, and January 26, 2011.

This "Prior Approval" supplemental new drug application provides for the revision of the Drug Interactions section of the label.

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert) with the addition of any labeling changes in pending "Changes Being Effectuated" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Mara Miller, Regulatory Project Manager, at (301) 796-0683.

Sincerely,

*{See appended electronic signature page}*

Ann Farrell, M.D.  
Division Director (Acting)  
Division of Hematology Products  
Office of Oncology Drug Products  
Center for Drug Evaluation and Research

ENCLOSURE:  
Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

ANN T FARRELL  
04/11/2011